Perioral Dermatitis Medication: Antibiotics, Other, Retinoid-Like Agents, Calcineurin Inhibitors, Tetracyclines, Anthelmintics, Topical antibiotic

Perioral dermatitis (POD) is a chronic papulopustular facial dermatitis. It mostly occurs in women and children.

Medication Summary

For mild disease, treatment can involve pimecrolimus, erythromycin, or metronidazole, either individually or in combination. Several small randomized controlled trials in adults support the efficacy of pimecrolimus in the treatment of perioral dermatitis  [14, 15] . Case reports have also suggested that tacrolimus may be effective. [25] Small randomized trials also support the efficacy of topical antibiotics such as erythromycin and clindamycin [16] and topical metronidazole. [17]  Case reports and small series have also suggested a potential role for topical azelaic acid  [26] and adapalene [27] , though these should be used cautiously given the potential for causing irritation.

While randomized trials are lacking in pediatric populations, observational data suggest that pimecrolimus and metronidazole can be effective treatment options. [28]

For those with more severe disease or who do not improve after 4-8 weeks of topical therapy, treatment with oral tetracyclines is often indicated. [16] Doxycycline is typically preferred over minocycline due to the lower risk of severe adverse effects. [29]  Emerging evidence suggests that sarecycline may also be a useful treatment option for perioral dermatitis. [30, 31] Sarecycline has a narrower spectrum of antibacterial activity than standard broad-spectrum antibiotics, which may reduce negative effects on the microbiome and the development of antibiotic resistance. [32]

Oral and topical ivermectin [18] , oral erythromycin [19] , oral and topical Janus kinase (JAK) inhibitors  [20, 21] , and oral isotretinoin [22, 23] have also been suggested as potential treatment options . 

eMedicine Logo

Antibiotics, Other

Class Summary

These drugs may have antibacterial and/or anti-inflammatory effects that are responsible for their effectiveness in perioral dermatitis.

Metronidazole (Flagyl)

  • View full drug information

Metronidazole is an imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. In concentrations of 0.75-2%, it is considered to be the drug of choice for topical treatment of perioral dermatitis. Metronidazole is available in a gel, lotion, or cream.

Erythromycin (E.E.S., Erythrocin, Ery-Tab)

  • View full drug information

Topical erythromycin in concentrations of 2-4% as a gel or cream is an alternative to metronidazole for topical treatment. It inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest. It is used to treat staphylococcal and streptococcal infections.

Clindamycin topical (Cleocin T, Clindacin P, ClindaDerm)

  • View full drug information

eMedicine Logo

Retinoid-Like Agents

Class Summary

These agents reduce the size of the sebaceous glands, decrease sebum secretion, and inhibit keratinization.

Isotretinoin (Amnesteem, Claravis, Sotret)

  • View full drug information

Isotretinoin is an oral agent used to treat serious dermatologic conditions. It is a synthetic 13-cis isomer of naturally occurring tretinoin (trans -retinoic acid). Both agents are structurally related to vitamin A. Isotretinoin decreases sebaceous gland size and sebum production. It may inhibit sebaceous gland differentiation and abnormal keratinization. Isotretinoin is indicated for long-standing and refractory forms of perioral dermatitis. Because of adverse effects, therapy should be prescribed only by a physician familiar with this drug (ie, dermatologist).

A US Food and Drug Administration–mandated registry is now in place for all individuals prescribing, dispensing, or taking isotretinoin. For more information on this registry, see iPLEDGE. This registry aims to further decrease the risk of pregnancy and other unwanted and potentially dangerous adverse effects during a course of isotretinoin therapy.

eMedicine Logo

Calcineurin Inhibitors

Tacrolimus ointment (Protopic)

  • View full drug information

Pimecrolimus (Elidel)

  • View full drug information

Pimecrolimus is the first nonsteroid cream approved in the United States for mild-to-moderate atopic dermatitis. It is derived from ascomycin, a natural substance produced by the fungus Streptomyces hygroscopicus var ascomyceticus. Pimecrolimus selectively inhibits the production and release of inflammatory cytokines from activated T-cells by binding to cytosolic immunophilin receptor macrophilin-12. The resulting complex inhibits phosphatase calcineurin, thus blocking T-cell activation and cytokine release. Cutaneous atrophy is not observed in clinical trials, a potential advantage over topical corticosteroids.

eMedicine Logo

Tetracyclines

Sarecycline (Seysara)

  • View full drug information

Doxycycline (Oracea, Doryx, Vibramycin)

  • View full drug information

Doxycycline is the drug of choice in nonpregnant women. It inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Alternatively, one may use tetracycline in adapted dose.

eMedicine Logo

Anthelmintics

eMedicine Logo

Topical antibiotic

eMedicine Logo

  1. Kihiczak GG, Cruz MA, Schwartz RA. Periorificial dermatitis in children: an update and description of a child with striking features. Int J Dermatol. 2009 Mar. 48(3):304-6. [QxMD MEDLINE Link].

  2. Tolaymat L, Hall MR. Perioral Dermatitis. StatPearls [Internet]. 2024 Jan. [QxMD MEDLINE Link]. [Full Text].

  3. Dirschka T, Tronnier H, Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004 Jun. 150(6):1136-41. [QxMD MEDLINE Link].

  4. Chen AY, Zirwas MJ. Steroid-induced rosacealike dermatitis: case report and review of the literature. Cutis. 2009 Apr. 83(4):198-204. [QxMD MEDLINE Link].

  5. Peralta L, Morais P. Perioral dermatitis -- the role of nasal steroids. Cutan Ocul Toxicol. 2012 Jun. 31(2):160-3. [QxMD MEDLINE Link].

  6. Beacham BE, Kurgansky D, Gould WM. Circumoral dermatitis and cheilitis caused by tartar control dentifrices. J Am Acad Dermatol. 1990 Jun. 22(6 Pt 1):1029-32. [QxMD MEDLINE Link].

  7. Malik R, Quirk CJ. Topical applications and perioral dermatitis. Australas J Dermatol. 2000 Feb. 41 (1):34-8. [QxMD MEDLINE Link].

  8. Baratli J, Megahed M. [Lupoid perioral dermatitis as a special form of perioral dermatitis : Review of pathogenesis and new therapeutic options.]. Hautarzt. 2013 Nov 9. [QxMD MEDLINE Link].

  9. Alniemi DT, Chen DL. Perioral Demodex folliculitis masquerading as perioral dermatitis in the peripartum period. JAAD Case Rep. 2019 Jul. 5 (7):639-641. [QxMD MEDLINE Link].

  10. Karincaoglu Y, Bayram N, Aycan O, Esrefoglu M. The clinical importance of demodex folliculorum presenting with nonspecific facial signs and symptoms. J Dermatol. 2004 Aug. 31(8):618-26. [QxMD MEDLINE Link].

  11. Antille C, Saurat JH, Lübbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol. 2004 Apr. 140(4):457-60. [QxMD MEDLINE Link].

  12. Lucas CR, Korman NJ, Gilliam AC. Granulomatous periorificial dermatitis: a variant of granulomatous rosacea in children?. J Cutan Med Surg. 2009 Mar-Apr. 13(2):115-8. [QxMD MEDLINE Link].

  13. Patel T, Singh Pathania Y, Goswami PR, Singh G, Dave R. Lupus Miliaris Disseminatus Faciei: A Report of a Rare Case and Its Differential Diagnosis. Cureus. 2024 Jun. 16 (6):e63245. [QxMD MEDLINE Link]. [Full Text].

  14. Schwarz T, Kreiselmaier I, Bieber T, et al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol. 2008 Jul. 59(1):34-40. [QxMD MEDLINE Link].

  15. Oppel T, Pavicic T, Kamann S, Brautigam M, Wollenberg A. Pimecrolimus cream (1%) efficacy in perioral dermatitis - results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol. 2007 Oct. 21(9):1175-80. [QxMD MEDLINE Link].

  16. Weber K, Thurmayr R, Meisinger A. A topical erythromycin preparation and oral tetracycline for the treatment of perioral dermatitis: a placebo-controlled trial. Journal of Dermatological Treatment. 1993. 4(2):57-59. [Full Text].

  17. Veien NK, Munkvad JM, Nielsen AO, Niordson AM, Stahl D, Thormann J. Topical metronidazole in the treatment of perioral dermatitis. J Am Acad Dermatol. 1991 Feb. 24 (2 Pt 1):258-60. [QxMD MEDLINE Link].

  18. Noguera-Morel L, Gerlero P, Torrelo A, Hernández-Martín Á. Ivermectin therapy for papulopustular rosacea and periorificial dermatitis in children: A series of 15 cases. J Am Acad Dermatol. 2017 Mar. 76 (3):567-570. [QxMD MEDLINE Link].

  19. Choi YL, Lee KJ, Cho HJ, Kim WS, Lee JH, Yang JM, et al. Case of childhood granulomatous periorificial dermatitis in a Korean boy treated by oral erythromycin. J Dermatol. 2006 Nov. 33 (11):806-8. [QxMD MEDLINE Link].

  20. Zundell MP, Al-Dehneem R, Song T, Yousif J, Gottlieb AB. Novel Clinical Applications of Topical Ruxolitinib: A Case Series. J Drugs Dermatol. 2024 Mar 1. 23 (3):188-190. [QxMD MEDLINE Link].

  21. Teng Y, Ren M, Ding Y, Yang X, Fan Y, Tao X. A Case of Perioral Dermatitis Successfully Treated with Abrocitinib. Clin Cosmet Investig Dermatol. 2023. 16:3035-3038. [QxMD MEDLINE Link].

  22. Smith KW. Perioral dermatitis with histopathologic features of granulomatous rosacea: successful treatment with isotretinoin. Cutis. 1990 Nov. 46(5):413-5. [QxMD MEDLINE Link].

  23. Rodriguez-Garijo N, Querol-Cisneros E, Tomas-Velazquez A, Estenaga A, Moreno-Artero E, Idoate MA, et al. Recalcitrant granulomatous periorificial dermatitis with good response to low-dose oral isotretinoin. Pediatr Dermatol. 2019 Nov. 36 (6):980-981. [QxMD MEDLINE Link].

  24. Sharma R, Abrol S, Wani M. Misuse of topical corticosteroids on facial skin. A study of 200 patients. J Dermatol Case Rep. 2017 Mar 31. 11 (1):5-8. [QxMD MEDLINE Link].

  25. Hussain W, Daly BM. Granulomatous periorificial dermatitis in an 11-year-old boy: dramatic response to tacrolimus. J Eur Acad Dermatol Venereol. 2007 Jan. 21 (1):137-9. [QxMD MEDLINE Link].

  26. Jansen T. Azelaic acid as a new treatment for perioral dermatitis: results from an open study. Br J Dermatol. 2004 Oct. 151(4):933-4. [QxMD MEDLINE Link].

  27. Jansen T. Perioral dermatitis successfully treated with topical adapalene. J Eur Acad Dermatol Venereol. 2002 Mar. 16 (2):175-7. [QxMD MEDLINE Link].

  28. Ollech A, Yousif R, Kruse L, Wagner A, Kenner-Bell B, Chamlin S, et al. Topical calcineurin inhibitors for pediatric periorificial dermatitis. J Am Acad Dermatol. 2020 Jun. 82 (6):1409-1414. [QxMD MEDLINE Link].

  29. Garner SE, Eady A, Bennett C, Newton JN, Thomas K, Popescu CM. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012 Aug 15. 2012 (8):CD002086. [QxMD MEDLINE Link].

  30. Swenson K, Stern A, Graber E. A Retrospective Review of a Cohort of Patients with Periorificial Dermatitis Treated with Sarecycline. J Clin Aesthet Dermatol. 2024 Jun. 17 (6):50-54. [QxMD MEDLINE Link]. [Full Text].

  31. Sher A, Kresch M, Bitterman D, Elbogen E, Lebwohl MG. Sarecycline as a Potential Treatment for Steroid-Induced Rosacea/Perioral Dermatitis: A Case Report. J Drugs Dermatol. 2024 Feb 1. 23 (2):e55-e56. [QxMD MEDLINE Link]. [Full Text].

  32. Zhanel G, Critchley I, Lin LY, Alvandi N. Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris. Antimicrob Agents Chemother. 2019 Jan. 63 (1):413-5. [QxMD MEDLINE Link].

  33. Abeck D, Geisenfelder B, Brandt O. Physical sunscreens with high sun protection factor may cause perioral dermatitis in children. J Dtsch Dermatol Ges. 2009 Aug. 7(8):701-3. [QxMD MEDLINE Link].

  34. Richey DF, Hopson B. Photodynamic therapy for perioral dermatitis. J Drugs Dermatol. 2006 Feb. 5(2 Suppl):12-6. [QxMD MEDLINE Link].

  35. Hafeez ZH. Perioral dermatitis: an update. Int J Dermatol. 2003 Jul. 42(7):514-7. [QxMD MEDLINE Link].

  36. Katsambas AD, Nicolaidou E. Acne, perioral dermatitis, flushing, and rosacea: unapproved treatments or indications. Clin Dermatol. 2000 Mar-Apr. 18(2):171-6. [QxMD MEDLINE Link].

Author

John Samuel Barbieri, MD, MBA Assistant Professor, Department of Dermatology, Harvard Medical School; Associate Physician, Department of Dermatology, Brigham and Women's Hospital; Physician, Department of Dermatology, Dana-Farber Cancer Institute; Founder and Director, Advanced Acne Therapeutics Clinic, Dana-Farber Cancer Institute

John Samuel Barbieri, MD, MBA is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology, Women's Dermatologic Society, American Acne and Rosacea Society, Pediatric Dermatology Research Alliance

Disclosure: Received income in an amount equal to or greater than $250 from: Honeydew Care.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

William D James, MD Emeritus Professor, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, American Contact Dermatitis Society, Association of Military Dermatologists, Association of Professors of Dermatology, American Dermatological Association, Women's Dermatologic Society, Medical Dermatology Society, Dermatology Foundation, Society for Investigative Dermatology, Washington DC Dermatological Society, Atlantic Dermatologic Society, Philadelphia Dermatological Society, Pennsylvania Academy of Dermatology, College of Physicians of Philadelphia

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier<br/>Served as a speaker for various universities, dermatology societies, and dermatology departments.

Additional Contributors

Hans J Kammler, MD, PhD Director and Professor, University Medical Center Bonn, Germany

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Almirall S.A.

Andrea Leigh Zaenglein, MD Professor of Dermatology and Pediatrics, Department of Dermatology, Hershey Medical Center, Pennsylvania State University College of Medicine

Andrea Leigh Zaenglein, MD is a member of the following medical societies: American Academy of Dermatology, Society for Pediatric Dermatology

Disclosure: Received consulting fee from Galderma for consulting; Received consulting fee from Valeant for consulting; Received consulting fee from Promius for consulting; Received consulting fee from Anacor for consulting; Received grant/research funds from Stiefel for investigator; Received grant/research funds from Astellas for investigator; Received grant/research funds from Ranbaxy for other; Received consulting fee from Ranbaxy for consulting.

Admin

Link nội dung: https://pi-web.eu/perioral-dermatitis-medication-antibiotics-other-retinoid-like-agents-calcineurin-inhibitors-tetracyclines-anthelmintics-topical-antibiotic-1732345210-a2059.html